Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GNI Group Ltd Announces Result for Phase 1b Clinical Trial of Liver Fibrosis Agent F351; Announces Patent Obtained by Subsidiary


Friday, 28 Jun 2013 03:55am EDT 

GNI Group Ltd announced the phase 1b result of clinical trial for liver fibrosis agent F351, which was conducted through a China-based subsidiary and shows the safety of F351. The Company will apply for approval from China Food and Drug Administration (CFDA) for a launch of phase II clinical trial on F351. The Company also announced that its Shanghai-based subsidiary has received a patent for manufacturing method of F351 in China. 

Company Quote

299.0
-5.0 -1.64%
2:00am EDT